Similar articles for PMID: 31924727

Year	Number of Results
2007	1
2010	1
2015	3
2016	12
2017	10
2018	24
2019	30
2020	14
2021	15
2022	8
2023	3
2024	0

1

Theranostics: Leveraging Molecular Imaging and Therapy to Impact Patient Management and Secure the Future of Nuclear Medicine.

Solnes LB, Werner RA, Jones KM, Sadaghiani MS, Bailey CR, Lapa C, Pomper MG, Rowe SP. Solnes LB, et al. J Nucl Med. 2020 Mar;61(3):311-318. doi: 10.2967/jnumed.118.220665. Epub 2020 Jan 10. J Nucl Med. 2020. PMID: 31924727 Free article. Review.

2

Theranostic approaches in nuclear medicine: current status and future prospects.

Filippi L, Chiaravalloti A, Schillaci O, Cianni R, Bagni O. Filippi L, et al. Expert Rev Med Devices. 2020 Apr;17(4):331-343. doi: 10.1080/17434440.2020.1741348. Epub 2020 Mar 19. Expert Rev Med Devices. 2020. PMID: 32157920 Review.

3

Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine.

Langbein T, Weber WA, Eiber M. Langbein T, et al. J Nucl Med. 2019 Sep;60(Suppl 2):13S-19S. doi: 10.2967/jnumed.118.220566. J Nucl Med. 2019. PMID: 31481583 Free article. Review.

4

More advantages in detecting bone and soft tissue metastases from prostate cancer using ¹⁸F-PSMA PET/CT.

Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE. Pianou NK, et al. Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7. Hell J Nucl Med. 2019. PMID: 30843003 Free article.

5

Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments.

Farolfi A, Fendler W, Iravani A, Haberkorn U, Hicks R, Herrmann K, Walz J, Fanti S. Farolfi A, et al. Eur Urol Oncol. 2019 Mar;2(2):152-162. doi: 10.1016/j.euo.2019.01.001. Epub 2019 Jan 31. Eur Urol Oncol. 2019. PMID: 31017091 Review.

6

TheraP: a randomized phase 2 trial of ¹⁷⁷ Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603).

Hofman MS, Emmett L, Violet J, Y Zhang A, Lawrence NJ, Stockler M, Francis RJ, Iravani A, Williams S, Azad A, Martin A, McJannett M; ANZUP TheraP team; Davis ID. Hofman MS, et al. BJU Int. 2019 Nov;124 Suppl 1:5-13. doi: 10.1111/bju.14876. Epub 2019 Oct 22. BJU Int. 2019. PMID: 31638341 Free article. Clinical Trial.

7

Recent Updates on Molecular Imaging Reporting and Data Systems (MI-RADS) for Theranostic Radiotracers-Navigating Pitfalls of SSTR- and PSMA-Targeted PET/CT.

Werner RA, Thackeray JT, Pomper MG, Bengel FM, Gorin MA, Derlin T, Rowe SP. Werner RA, et al. J Clin Med. 2019 Jul 19;8(7):1060. doi: 10.3390/jcm8071060. J Clin Med. 2019. PMID: 31331016 Free PMC article. Review.

8

The Search for an Alternative to [⁶⁸Ga]Ga-DOTA-TATE in Neuroendocrine Tumor Theranostics: Current State of ¹⁸F-labeled Somatostatin Analog Development.

Waldmann CM, Stuparu AD, van Dam RM, Slavik R. Waldmann CM, et al. Theranostics. 2019 Feb 14;9(5):1336-1347. doi: 10.7150/thno.31806. eCollection 2019. Theranostics. 2019. PMID: 30867834 Free PMC article. Review.

9

An Impressive Approach in Nuclear Medicine: Theranostics.

Vahidfar N, Eppard E, Farzanehfar S, Yordanova A, Fallahpoor M, Ahmadzadehfar H. Vahidfar N, et al. PET Clin. 2021 Jul;16(3):327-340. doi: 10.1016/j.cpet.2021.03.011. PET Clin. 2021. PMID: 34053577 Review.

10

PSMA Theranostics: Current Status and Future Directions.

Rahbar K, Afshar-Oromieh A, Jadvar H, Ahmadzadehfar H. Rahbar K, et al. Mol Imaging. 2018 Jan-Dec;17:1536012118776068. doi: 10.1177/1536012118776068. Mol Imaging. 2018. PMID: 29873291 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

106 results

Results by year